Literature DB >> 22456585

Cognitive impairments in schizophrenia and schizoaffective disorder: relationship with clinical characteristics.

Minna Torniainen1, Jaana Suvisaari, Timo Partonen, Anu E Castaneda, Annamaria Kuha, Jaana Suokas, Jonna Perälä, Samuli I Saarni, Jouko Lönnqvist, Annamari Tuulio-Henriksson.   

Abstract

The present study aimed to compare population-based familial samples of patients with schizophrenia (n = 218) and schizoaffective disorder (n = 62) and a healthy control group (n = 123). Patients with schizoaffective disorder outperformed patients with schizophrenia in verbal ability, processing speed, visual working memory, and verbal memory. When compared with controls, patients with schizoaffective disorder also had a generalized cognitive impairment. Adjusting for clinical characteristics removed significant differences between the patient groups. Irrespective of the diagnosis, patients with the most severe negative symptoms and highest dose of antipsychotics had the most severe cognitive impairments, whereas mood symptoms were not related to cognitive performance. In conclusion, people with schizoaffective disorder have severe cognitive impairments, but the impairments are milder than in schizophrenia. Mood symptoms may not explain the difference between the diagnostic groups in cognitive functions, but the difference may be related to differences in the severity of negative symptoms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22456585     DOI: 10.1097/NMD.0b013e31824cb359

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  11 in total

1.  Characteristics and Service Use of Older Adults with Schizoaffective Disorder Versus Older Adults with Schizophrenia and Bipolar Disorder.

Authors:  Stephanie A Rolin; Kelly A Aschbrenner; Karen L Whiteman; Emily Scherer; Stephen J Bartels
Journal:  Am J Geriatr Psychiatry       Date:  2017-04-03       Impact factor: 4.105

2.  Lifetime cannabis use and cognition in patients with schizophrenia spectrum disorders and their unaffected siblings.

Authors:  Ana M Sánchez-Torres; Virginia Basterra; Araceli Rosa; Lourdes Fañanás; Amalia Zarzuela; Berta Ibáñez; Víctor Peralta; Manuel J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-04-12       Impact factor: 5.270

Review 3.  The global cognitive impairment in schizophrenia: consistent over decades and around the world.

Authors:  Jonathan Schaefer; Evan Giangrande; Daniel R Weinberger; Dwight Dickinson
Journal:  Schizophr Res       Date:  2013-08-02       Impact factor: 4.939

Review 4.  The dynamics of DNA methylation in schizophrenia and related psychiatric disorders.

Authors:  Dennis R Grayson; Alessandro Guidotti
Journal:  Neuropsychopharmacology       Date:  2012-09-05       Impact factor: 7.853

5.  Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort.

Authors:  Anja P Husa; Jani Moilanen; Graham K Murray; Riikka Marttila; Marianne Haapea; Irina Rannikko; Jennifer H Barnett; Peter B Jones; Matti Isohanni; Anne M Remes; Hannu Koponen; Jouko Miettunen; Erika Jääskeläinen
Journal:  Psychiatry Res       Date:  2016-11-12       Impact factor: 3.222

Review 6.  The effects of arousal on apical amplification and conscious state.

Authors:  W A Phillips; M E Larkum; C W Harley; S M Silverstein
Journal:  Neurosci Conscious       Date:  2016-09-11

7.  Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion.

Authors:  Tanja Veselinović; Ingo Vernaleken; Paul Cumming; Uwe Henning; Lina Winkler; Peter Kaleta; Michael Paulzen; Christian Luckhaus; Gerhard Gründer
Journal:  Neuropsychiatr Dis Treat       Date:  2018-04-27       Impact factor: 2.570

8.  Cognitive functioning correlates of self-esteem and health locus of control in schizophrenia.

Authors:  Chien-Shu Wang; Jo Yung-Wei Wu; Wei-Chung Chang; Shu-Ping Chuang
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-29       Impact factor: 2.570

9.  Dysfunction of Cognition Patterns Measured by MATRICS Consensus Cognitive Battery (MCCB) among First Episode Schizophrenia Patients and Their Biological Parents.

Authors:  Aiai Cao; Ting Shen; Haibin Li; Chuangxin Wu; Marita McCabe; David Mellor; Linda Byrne; Jie Zhang; Jia Huang; Daihui Peng; Yifeng Xu
Journal:  Shanghai Arch Psychiatry       Date:  2017-06-25

10.  Metacognitive Beliefs, Cognitive Functioning, Psychiatric Symptoms and Empathy in People with Schizophrenia.

Authors:  Shu Ping Chuang; Jo Yung Wei Wu; Chien Shu Wang
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-07       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.